PREMARIN TABLETS 0.9MG 0.9 MG
CONJUGATED ESTROGENS : 0.9 MG · DIN 02043416 · WYETH CANADA
Health Canada status: CANCELLED POST MARKET
What is PREMARIN TABLETS 0.9MG?
PREMARIN TABLETS 0.9MG 0.9 MG contains CONJUGATED ESTROGENS : 0.9 MG. It is listed in the Health Canada Drug Product Database under DIN 02043416, held by WYETH CANADA, supplied as TABLET for ORAL administration. Health Canada currently lists it as cancelled post market, status dated 13-Aug-2007. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What is PREMARIN TABLETS 0.9MG used for?
Relief of menopausal symptoms; prevention of osteoporosis; hypoestrogenism; atrophic vaginitis; vulvar atrophy. Use lowest effective dose for shortest duration.
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
Product details and regulatory record
| DIN | 02043416 |
|---|---|
| Brand name | PREMARIN TABLETS 0.9MG |
| Generic / active ingredient | CONJUGATED ESTROGENS : 0.9 MG |
| Manufacturer | WYETH CANADA |
| Strength | 0.9 MG |
| Dosage form | TABLET |
| Route of administration | ORAL |
| Schedule | Prescription |
| ATC code | G03CA57 CONJUGATED ESTROGENS |
| Biosimilar | No |
| Health Canada status | CANCELLED POST MARKET |
| Status date | 13-Aug-2007 |
How is it administered?
Prescribe at lowest effective dose for shortest duration. In patients with an intact uterus, Premarin should be prescribed with an appropriate dosage of a progestin.
Included because it drives pack selection and wastage. Consult the monograph.
How is it stored and handled?
Not explicitly stated in the provided text (refer to Storage and Stability section 26).
How is it supplied?
0.3 mg, 0.625 mg, 0.9 mg, and 1.25 mg tablets (Specific container sizes not provided in excerpt).
Contraindications
Liver dysfunction; estrogen-dependent neoplasia; endometrial hyperplasia; breast cancer; undiagnosed genital bleeding; pregnancy; active/past VTE or arterial thromboembolic disease; vision loss.
Warnings and precautions
Increased risk of MI, stroke, invasive breast cancer, and VTE. Not for cardiovascular disease prevention. Risk of endometrial cancer in women with intact uteri if used without progestin.
What can be used instead?
Other Canadian products sharing ATC code G03CA57 CONJUGATED ESTROGENS. 4 of 33 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.
| Product | Strength | Form | Manufacturer | Health Canada status | DIN |
|---|---|---|---|---|---|
| PREMARIN | 0.3 MG | TABLET (EXTENDED-RELEASE) | PFIZER CANADA ULC | MARKETED | DIN 02414678 |
| PREMARIN | 1.25 MG | TABLET (EXTENDED-RELEASE) | PFIZER CANADA ULC | MARKETED | DIN 02414694 |
| PREMARIN INTRAVENOUS | 25 MG | POWDER FOR SOLUTION | PFIZER CANADA ULC | MARKETED | DIN 02043386 |
| PREMARIN VAGINAL CREAM | 0.625 MG | Cream | PFIZER CANADA ULC | MARKETED | DIN 02043440 |
| APO-CONEST TAB 0.3MG | 0.3 MG | TABLET | APOTEX INC | CANCELLED POST MARKET | DIN 00798231 |
| APO-CONEST TAB 0.625MG | 0.625 MG | TABLET | APOTEX INC | CANCELLED POST MARKET | DIN 00798223 |
| APO-CONEST TAB 0.9MG | 0.9 MG | TABLET | APOTEX INC | CANCELLED POST MARKET | DIN 00798215 |
| APO-CONEST TAB 1.25MG | 1.25 MG | TABLET | APOTEX INC | CANCELLED POST MARKET | DIN 00798207 |
| APO-CONEST TAB 2.5MG | 2.5 MG | TABLET | APOTEX INC | CANCELLED POST MARKET | DIN 00798193 |
| C.E.S. | 0.625 MG | TABLET | BAUSCH HEALTH, CANADA INC. | DORMANT | DIN 00265470 |
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.